-David Johnson joins Board of Directors; Noel Hall appointed Board Chair
VANCOUVER, CANADA – June 27, 2022 – Incisive Genetics Inc. (“IG”), a privately held biotech company specializing in the research and development of a novel non-viral delivery platform for targeted CRISPR-based gene therapies, today announced the close of a $12 million CAD financing. The financing round was led by the MacHall Group and the Robinson Sauder Family Office, with participation from Velosity Capital Management and Saltagen Ventures.
“We are pleased to have this strong investor syndicate to support our continued growth and advancement,” said Dr. Blair R. Leavitt, co-founder and CEO of Incisive Genetics. “To date, we’ve made significant progress in establishing the ex vivo and in vivo efficacy of the Incisive Delivery System™, our novel approach to deliver active CRISPR ribonucleoprotein complexes using lipid nanoparticles. With this additional financing we look forward to furthering the development of our core technology towards future potential curative therapies for genetic diseases.”
The funding bolsters IG’s initial $2.5 million CAD seed financing and will allow the Company to continue exploring technology applications across various organs and tissues, developing its manufacturing process and capabilities, evaluate potential drug candidates for future clinical development, further enhance intellectual property, and allow for facility expansion and hiring of new employees.
In conjunction with the financing, David Johnson of Velosity Capital will join as Board Director and current Lead Director Mr. Hall will assume the role of Chair of the Board. Mr. Johnson, currently founder and CEO of Solve Therapeutics, previously served as CEO and founder of VelosBio prior to its acquisition by Merck and as CEO of Acerta Pharma prior to its acquisition by AstraZeneca.
“IG’s proprietary technology platform offers an innovative delivery system to realize the potential of genome editing, and we are delighted to continue to support the IG team as they scale up operations and technology development,” said Noel Hall, of the MacHall Group.
About Incisive Genetics Inc.
Incisive Genetics, a privately held biotechnology company based in Vancouver, Canada, was established in 2018. IG is focused on developing a cutting-edge non-viral delivery platform for genetic therapies. This disruptive and transformational delivery platform enables a one-step encapsulation of the active CRISPR components within lipid nanoparticles. The Company’s pre-clinical pipeline includes programs addressing neurologic and ocular genetic diseases. IG is actively seeking partnerships with pharmaceutical companies developing gene therapies to be enabled by its novel delivery platform.
For more information, please contact
Austin Hill
info@incisivegenetics.com
604-409-0660
